juluca dolutegravir sodium 50 mg rilpivirine hydrochloride 25 mg tablet film coated

1 INDICATIONS AND USAGE JULUCA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA. JULUCA, a two-drug combination of dolutegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), is indicated as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA. ( 1 )

viiv healthcare company

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] toxicity to various agents` `[3] off label use` `[4] completed suicide` `[5] drug abuse` `[6] nausea` `[7] product use in unapproved indication` `[8] pyrexia` `[9] diarrhoea` `[10] death`

3 years ago

OVAL PINK SV J3T

16 HOW SUPPLIED/STORAGE AND HANDLING Each JULUCA tablet contains 50 mg of dolutegravir and 25 mg of rilpivirine, and is a pink, oval, film-coated, biconvex tablet debossed with “SV J3T” on one side. Bottle of 30 tablets with child-resistant closure (contains a desiccant) NDC 49702-242-13. Store and dispense in the original package, protect from moisture, and keep the bottle tightly closed. Do not remove desiccant. Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [See USP Controlled Room Temperature].

More pills like OVAL SV J3T

DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site

juluca dolutegravir sodium 50 mg rilpivirine hydrochloride 25 mg tablet film coated

FDA Reported Adverse Reactions [1] drug ineffective [2] toxicity to various agents [3] off label use [4] completed suicide [5] drug abuse [6] nausea [7] product use in unapproved indication [8] pyrexia [9] diarrhoea [10] death

OVAL PINK SV J3T

More pills like OVAL SV J3T

FDA Reported Adverse Reactions
`[1] drug ineffective` `[2] toxicity to various agents` `[3] off label use` `[4] completed suicide` `[5] drug abuse` `[6] nausea` `[7] product use in unapproved indication` `[8] pyrexia` `[9] diarrhoea` `[10] death`